DOACs an effective substitute for VKAs after AFib patients undergo bioprosthetic valve replacement

Direct oral anticoagulants (DOACs) may be an effective anticoagulation strategy for atrial fibrillation (AFib) patients who undergo bioprosthetic valve replacement, according to a new meta-analysis published in the American Journal of Cardiology.[1]

“Anticoagulation strategies in patients with AFib who underwent bioprosthetic valve replacement are still controversial,” wrote lead author Safia Shaikh, MD, an internal medicine specialist with SSM Health St. Mary's Hospital - St. Louis, and colleagues. “Despite dramatic increase in volume, postoperative anticoagulation continues to be a challenge.”

The group also emphasized that many recommendations for anticoagulation in this patient population have been powered by “limited evidence” from “small, underpowered” studies. A meta-analysis, they hoped, could better context that could help clinicians provide the best care possible.

Shaikh et al. examined data from three randomized controlled trials. The total cohort included nearly 2,500 patients, and 50% were treated with DOACs. The remaining patients were prescribed an anticoagulation strategy that included vitamin K antagonists (VKAs), a more traditional strategy, instead of DOACs. The mean patient age was 72.4 years old, and 53% were women. The mean follow-up period was 16 months.

Two different specialists extracted the data independently of one another. The team’s primary outcome was all-cause mortality, but secondary outcomes included such complications as stroke/systemic embolization, intracardiac thrombosis and bleeding events.

Overall, there was “no difference” between DOAC and VKA patients when it came to all-cause mortality, stroke/systemic embolization, intracardiac thrombosis and bleeding events. This finding, the authors noted, showed that a strategy focused on DOAC is noninferior to one focused on VKA when AFib patients undergo bioprosthetic valve replacement.

“Our analyses showed similar therapeutic efficacy and safety profile for anticoagulation with VKA and DOAC in this subset of patients,” the authors wrote. “Ability to substitute VKA with DOAC is important to avoid the narrow therapeutic index, drug interactions, genetic variants, and need for blood monitoring with VKA. DOACs have a better pharmacologic profile in terms of feasibility and convenience.”

Related Heart Rhythm Content:

CRT-D associated with major improvements among older HFrEF patients

Electrophysiologists debut new technology that builds interactive cardiac maps out of 12-lead ECGs

Holter monitor for low-risk patients gains FDA clearance

Rest easy, heart patients — sudden cardiac death rarely happens during sex

 

Reference:

1. Safia Shaikh, MD, Mohamed M.G. Mohamed, MD, Mohammed Osman, MD, et al. Meta-Analysis Comparing Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients With Atrial Fibrillation Who Underwent Bioprosthetic Valve Replacement. j.amjcard.2022.01.00

Michael Walter
Michael Walter, Managing Editor

Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup